Marine Drug and Food Institute, Ocean University of China, Qingdao, China.
Acta Pharmacol Sin. 2010 Nov;31(11):1500-7. doi: 10.1038/aps.2010.113. Epub 2010 Oct 18.
To investigate the population pharmacokinetics of recombinant human tumor necrosis factor receptor-Fc fusion protein (rhTNFR-Fc) administered via subcutaneous (SC) injection in healthy Chinese volunteers and in Chinese patients with ankylosing spondylitis (AS).
Thirty-two healthy volunteers were randomly assigned to receive a single SC injection of 12.5, 25, 37.5, or 50 mg of rhTNFR-Fc. Twenty male patients with moderate AS were randomly assigned to receive seven consecutive SC injections of rhTNFR-Fc at either 25 mg twice a week (BIW) or 50 mg once a week (QW). Population pharmacokinetic (PK) analysis was applied to obtain PK parameters of rhTNFR-Fc by the NONMEM method.
The data were best described by a one-compartment model with lag time. We found that gender had a significant effect on the apparent clearance (CL/F), with the male CL/F ratio being only 0.665 times the female ratio; the absorption coefficient (F) of multiple dosages of rhTNFR-Fc was only 0.674 times that of a single dosage. The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h). The inter-individual variability in the CL/F, Vd/F, Ka, and T(lag) were 33.3%, 42.7%, 55.6%, and 81.8%, respectively.
Chinese females have a higher CL/F than Chinese males, and multiple dosings can significantly decrease the absorption of rhTNFR-Fc (SC). The population PK parameters of rhTNFR-Fc in healthy Chinese volunteers and patients with AS were similar to those reported for subjects in published American studies.
研究重组人肿瘤坏死因子受体 -Fc 融合蛋白(rhTNFR-Fc)在中国健康志愿者和强直性脊柱炎(AS)患者中的皮下(SC)注射的群体药代动力学。
32 名健康志愿者被随机分配接受单次 SC 注射 12.5、25、37.5 或 50mg rhTNFR-Fc。20 名男性中度 AS 患者被随机分配接受 rhTNFR-Fc 连续 7 次 SC 注射,每周 2 次 25mg(BIW)或每周 1 次 50mg(QW)。通过 NONMEM 法进行群体药代动力学(PK)分析,获得 rhTNFR-Fc 的 PK 参数。
数据最好用具有滞后时间的单室模型来描述。我们发现,性别对表观清除率(CL/F)有显著影响,男性 CL/F 比值仅为女性的 0.665 倍;rhTNFR-Fc 的多次剂量的吸收系数(F)仅为单次剂量的 0.674 倍。结果参数为 CL/F(女性:0.168L/h,男性:0.110L/h)、表观分布容积(Vd/F:15.5L)、吸收速率常数(Ka)(单次剂量:0.0605h⁻¹,多次剂量:0.0408h⁻¹)和滞后时间(T(lag):1.03h)。CL/F、Vd/F、Ka 和 T(lag)的个体间变异性分别为 33.3%、42.7%、55.6%和 81.8%。
中国女性的 CL/F 高于中国男性,多次剂量可显著降低 rhTNFR-Fc(SC)的吸收。健康中国志愿者和 AS 患者的 rhTNFR-Fc 群体 PK 参数与已发表的美国研究中报告的参数相似。